30
edits
Difference between revisions of "Neuroendocrine tumour of the pancreas"
Jump to navigation
Jump to search
Neuroendocrine tumour of the pancreas (view source)
Revision as of 20:21, 3 March 2019
, 20:21, 3 March 2019→WHO classification of 2017
(→IHC) |
|||
| Line 47: | Line 47: | ||
===WHO classification of 2017=== | ===WHO classification of 2017=== | ||
Five | Five categories:<!-- https://www.esp-congress.org/fileadmin/user_upload/Congress_2016/IAP_ESP_Presentations/Mon/0830-1200/SY-02/SY-02-004-Kl%C3%B6ppel-Update%20of%20WHO%20classification%20of%20endocrine%20pancreatic%20tumours.pdf --> | ||
*NET G1. | *NET G1. Ki67 Index < 3%, Mitotic Index < 2/10HPF | ||
*NET G2. | *NET G2. Ki67 Index 3-20%, Mitotic Index 2-20/10HPF | ||
*NET G3. | *NET G3. Ki67 Index > 20%, Mitotic Index > 20/10 HPF AND well-differentiated, expressing neuroendocrine differentiation and hormones | ||
*Neuroendocrine carcinoma. | *Neuroendocrine carcinoma (NEC G3). Ki 67 Index > 20%, Mitotic Index > 20/10 HPF Poorly differentiated, expressing neuroendocrine differentiation but lacking exocrine markers. | ||
*[[MiNEN]]. | *[[MiNEN]]. mixed endocrine-nonendocrine neoplasm: components of a non-endocrine carcinoma (mostly ductal adenocarcinoma or acinar cell carcinoma) combined with a neuroendocrine neoplasm | ||
===Classification by product=== | ===Classification by product=== | ||